Data / Drug companies / Acrotech Biopharma Inc
Acrotech Biopharma Inc: 8 products in the FDA NDC directory, labeler code 72893
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Acrotech Biopharma Inc (labeler code 72893) lists 8 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 8 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on February 25, 2026.
The request: Watch Acrotech Biopharma Inc (FDA labeler code 72893): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72893
- Products in commercial distribution
- 8
- Packages
- 10
- Finished drugs by generic name
- 7
- Prescription products
- 8
- Over the counter products
- 0
- Flagged as original packager
- 4 of 4 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- February 19, 2002
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 6 | 75% |
| Biologics (BLA) | 2 | 25% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 8 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Pralatrexate | 2 | 3 |
| Melphalan | 1 | 1 |
| Ibritumomab tiuxetan | 1 | 1 |
| Levoleucovorin | 1 | 5 |
| Difamilast | 1 | 1 |
| Efbemalenograstim alfa-vuxw | 1 | 1 |
| Belinostat | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 3 | 37.5% |
| Injection | 3 | 37.5% |
| Kit | 1 | 12.5% |
| Ointment | 1 | 12.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Folate Analog Metabolic Inhibitor | 2 |
| Alkylating Drug | 1 |
| Folate Analog | 1 |
| Phosphodiesterase 4 Inhibitor | 1 |
| Leukocyte Growth Factor | 1 |
| Histone Deacetylase Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Adquey | 72893-017 | Ointment | New drug applications (NDA) | February 25, 2026 |
| Ryzneuta | 72893-016 | Injection | Biologics (BLA) | November 23, 2023 |
| Khapzory | 72893-004 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | January 2, 2019 |
| Evomela | 72893-001 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | March 31, 2016 |
| Beleodaq | 72893-002 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | July 21, 2014 |
| Folotyn | 72893-005 | Injection | New drug applications (NDA) | September 24, 2009 |
| Folotyn | 72893-003 | Injection | New drug applications (NDA) | September 24, 2009 |
| Zevalin | 72893-007 | Kit | Biologics (BLA) | February 19, 2002 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.